Enigmatic ImClone

Enigmatic ImClone
Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. But such is the case with ImClone Systems, as investors struggle for clues on the long-term direction of this enigma.

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog